Skip to main content
Solid Tumor Central Nervous System Cancer

Central Nervous System Cancer

Open Access Spinal Tumor Case Study

Misdiagnosis of MMNST of the cervical spinal cord

Malignant melanotic nerve sheath tumors are rare and highly aggressive. In this case MMNST was misdiagnosed as a benign vascular malformation, then recurred 7 months after resection.

Editor's Choice

Low-grade glioma in adolescents and young adults

Glioma Review

25% of gliomas in adolescents and young adults are pediatric-type LGG. Should treatment in this older age group be the same as in children?

Improving drug delivery in glioblastoma

Open Access Glioblastoma Review

Glioblastoma remains resistant to most conventional treatments. Emerging therapies target the blood–brain barrier and tumor microenvironment.

Novel therapies for glioblastoma

Recent clinical trials in glioblastoma have investigated a wide variety of therapeutic options, such as targeted agents, immunotherapies, and vaccine-based therapies. Find out more in this review.

Antiepileptic strategies for patients with brain tumors

Epilepsy due to primary or metastatic brain tumors accounts for 6–10% of all cases of epilepsy. Levetiracetam monotherapy is the initial treatment of choice, but other pharmacologic and nonpharmacologic options are also available.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare

Case Studies

Misdiagnosis of MMNST of the cervical spinal cord

Open Access Spinal Tumor Case Study

Malignant melanotic nerve sheath tumors are rare and highly aggressive. In this case MMNST was misdiagnosed as a benign vascular malformation, then recurred 7 months after resection.

Diffuse large B‑cell lymphoma of the CNS

Open Access Diffuse Large B-Cell Lymphoma Case Study

A 68-year-old woman was admitted to the emergency department with headache, mental confusion, and a mild hemiparesis. Explore the imaging findings, differential diagnosis, and histopathological findings that revealed the patient’s diagnosis.

​Occult extracranial malignancy after complete remission of pineal mixed germ cell tumors

Open Access Pediatric Cancer Case Study

Intracranial GCTs developed occult extracranial malignancy with negative tumor markers, indicating that tumor marker monitoring may need to be combined with regular follow-up abdominal imaging for early detection.

Case-Based Insights: Oncology and Hematology (Link opens in a new window)


Refresh your knowledge in Oncology and Hematology: 

  • 45 clinical cases across different topics with relevant clinical images
  • Written by renowned experts 
  • Knowledge-check questions with answers
Try the first set of cases now

Current Reviews

Patient-Centered Management of Brain Tumor-Related Epilepsy

Epilepsy Review

Brain-tumor related epilepsy (BTRE) is a heterogenous syndrome associated with primary and metastatic brain tumors, accounting for 6–10% of all cases of epilepsy [ 1 ], with an average annual age-adjusted incidence rate of 24.71 per 100,000 [ 2 ].

Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine

Open Access Glioblastoma REVIEW

Isocitrate dehydrogenase wild-type glioblastoma (GBM) is the most common and aggressive primary brain tumour in adults, comprising 49% of brain malignancy [ 1 ] with a dismal median survival rate of 14 months from diagnosis [ 2 ]. The current …

Prognostic value of surgical resection over biopsy in elderly patients with glioblastoma: a meta-analysis

Glioblastoma (GBM), the most common malignant primary brain tumor [ 1 , 2 ], has a dismal prognosis in older adults when compared to younger patients [ 3 ]. In the elderly, the survivorship for newly-diagnosed GBM is less than 6 months, even with …

Awake craniotomy in pediatric low-grade glioma: barriers and future directions

Pediatric low-grade gliomas (pLGGs) are the most common intracranial tumors in children, constituting one-third of such lesions [ 1 ]. pLGGs are a heterogeneous group of tumors and can vary by tumor histology and World Health Organization (WHO) …

Webinar | 16-05-2023 | 17:30 (CEST)

Keynote webinar | Spotlight on cardio-oncology

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.

Prof. Rudolf de Boer
Prof. Lorenz Lehmann
Dr. Teresa Lopéz Fernández

Further Reading

Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine

Open Access Glioblastoma REVIEW

Isocitrate dehydrogenase wild-type glioblastoma (GBM) is the most common and aggressive primary brain tumour in adults, comprising 49% of brain malignancy [ 1 ] with a dismal median survival rate of 14 months from diagnosis [ 2 ]. The current …

Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant

Open Access Astrocytoma Research

The 2016 update of the World Health Organization (WHO) classification of central nervous system (CNS) tumors marked a pivotal shift in brain tumor diagnosis, transitioning from traditional histopathologic classification to molecular genetic …

Radiomics and visual analysis for predicting success of transplantation of heterotopic glioblastoma in mice with MRI

Open Access Glioblastoma Research

Magnetic resonance imaging (MRI) represents the noninvasive gold standard method for diagnosing, planning the treatment, and monitoring the therapy of brain tumors [ 1 , 2 ]. MRI is also gaining increasing importance for studying tumor growth and …

Effect of radiochemotherapy on peripheral immune response in glioblastoma

Open Access Glioblastoma Research

Glioblastoma (GBM) is the most frequent and most aggressive primary brain tumor. Treatment is based on surgery, consisting of complete removal of the gross tumor mass whenever possible. Following surgery, treatment is pursued with a combination of …